Page 47 - MI-2-1

Microbes & Immunity iPSC-derived NK cell immunotherapy

40. Takahashi K, Yamanaka S. Induction of pluripotent stem microRNA-183 silences tumor-associated natural killer cells.
cells from mouse embryonic and adult fibroblast cultures by Proc Natl Acad Sci U S A. 2014;111(11):4203-4208.
defined factors. Cell. 2006;126(4):663-676.
doi: 10.1073/pnas.1319269111
doi: 10.1016/j.cell.2006.07.024 52. Lee YS, Choi H, Cho HR, et al. Downregulation of NKG2DLs
41. Zhu H, Kaufman DS. An Improved method to produce by TGF-beta in human lung cancer cells. BMC Immunol.
clinical-scale natural killer cells from human pluripotent 2021;22(1):44.
stem cells. Methods Mol Biol. 2019;2048:107-119.
doi: 10.1186/s12865-021-00434-8
doi: 10.1007/978-1-4939-9728-2_12
53. Bai X, Jing L, Li Y, et al. TMEPAI inhibits TGF-β signaling
42. Cichocki F, van der Stegen SJC, Miller JS. Engineered and by promoting lysosome degradation of TGF-β receptor
banked iPSCs for advanced NK- and T-cell immunotherapies. and contributes to lung cancer development. Cell Signal.
Blood. 2023;141(8):846-855. 2014;26(9):2030-2039.
doi: 10.1182/blood.2022016205 doi: 10.1016/j.cellsig.2014.06.001
43. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. 54. Song P, Fan K, Tian X, Wen J. Bisphenol S (BPS) triggers
Annu Rev Immunol. 2002;20:323-370. the migration of human non-small cell lung cancer cells via
upregulation of TGF-β. Toxicol In Vitro. 2019;54:224-231.
doi: 10.1146/annurev.immunol.20.100201.131730
doi: 10.1016/j.tiv.2018.10.005
44. Rosenberg J, Huang J. CD8 T Cells and NK cells: Parallel
+
and complementary soldiers of immunotherapy. Curr Opin 55. Chen W, Zhang Y, Fang Z, Qi W, Xu Y. TRIM66 hastens
Chem Eng. 2018;19:9-20. the malignant progression of non-small cell lung cancer
via modulating MMP9-mediated TGF-β/SMAD pathway.
doi: 10.1016/j.coche.2017.11.006
Cytokine. 2022;153:155831.
45. Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L.
Effect of tumor cells and tumor microenvironment on doi: 10.1016/j.cyto.2022.155831
NK-cell function. Eur J Immunol. 2014;44(6):1582-1592. 56. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-
dependent stimulation and inhibition of dendritic cells by
doi: 10.1002/eji.201344272
natural killer cells. J Exp Med. 2002;195(3):335-341.
46. Fu B, Wang F, Sun R, Ling B, Tian Z, Wei H. CD11b and CD27 doi: 10.1084/jem.20010934
reflect distinct population and functional specialization in
human natural killer cells. Immunology. 2011;133(3):350-359. 57. Carbone E, Terrazzano G, Ruggiero G, et al. Recognition
of autologous dendritic cells by human NK cells. Eur J
doi: 10.1111/j.1365-2567.2011.03446.x
Immunol. 1999;29(12):4022-4029.
47. Rezaeifard S, Talei A, Shariat M, Erfani N. Tumor infiltrating
NK cell (TINK) subsets and functional molecules in patients doi: 10.1002/(SICI)1521-4141(199912)29:12<4022:AID-
with breast cancer. Mol Immunol. 2021;136:161-167. IMMU4022>3.0.CO;2-O
58. Russick J, Joubert PE, Gillard-Bocquet M, et al. Natural
doi: 10.1016/j.molimm.2021.03.003
killer cells in the human lung tumor microenvironment
48. Jin J, Fu B, Mei X, et al. CD11b(-)CD27(-) NK cells are display immune inhibitory functions. J Immunother Cancer.
associated with the progression of lung carcinoma. PLoS 2020;8(2):e001054.
One. 2013;8(4):e61024.
doi: 10.1136/jitc-2020-001054
doi: 10.1371/journal.pone.0061024
59. Starnes T, Rasila KK, Robertson MJ, et al. The chemokine
49. Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT. CXCL14 (BRAK) stimulates activated NK cell migration:
TGF-beta downregulates the activating receptor NKG2D on Implications for the downregulation of CXCL14 in
+
NK cells and CD8 T cells in glioma patients. Neuro Oncol. malignancy. Exp Hematol. 2006;34(8):1101-1105.
2010;12(1):7-13.
doi: 10.1016/j.exphem.2006.05.015
doi: 10.1093/neuonc/nop009
60. Wang H, Nan S, Wang Y, Xu C. CDX2 enhances natural
50. Brownlie D, Doughty-Shenton D, Yh Soong D, et al. killer cell-mediated immunotherapy against head and neck
Metastasis-associated macrophages constrain antitumor squamous cell carcinoma through up-regulating CXCL14.
capability of natural killer cells in the metastatic site at least J Cell Mol Med. 2021;25(10):4596-4607.
partially by membrane bound transforming growth factor β. doi: 10.1111/jcmm.16253
J Immunother Cancer. 2021;9(1):e001740.
61. Tejchman A, Lamerant-Fayel N, Jacquinet JC, et al. Tumor
doi: 10.1136/jitc-2020-001740
hypoxia modulates podoplanin/CCL21 interactions
51. Donatelli SS, Zhou JM, Gilvary DL, et al. TGF-beta-inducible in CCR7 NK cell recruitment and CCR7 tumor cell
+
+
Volume 2 Issue 1 (2025) 39 doi: 10.36922/mi.5653